Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Opinions+
STAT+

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

  • Elizabeth Cooney

By Elizabeth Cooney Aug. 16, 2018

Reprints
D.C. Insight IMAGE
Alex Hogan/STAT

STAT Plus subscribers, we want to know what you think.

The last time we polled you, the new tax law was wending its way through Congress, Tom Price still had a seat in the Trump cabinet, and PhRMA was launching its “Go Boldly” campaign on the heels of a hike in membership fees.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Elizabeth Cooney

Elizabeth Cooney

Reporter, Morning Rounds Writer

Liz Cooney is the author of STAT's Morning Rounds newsletter.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Long-term study shows most prostate cancer patients don’t need…
Long-term study shows most prostate cancer patients don’t need aggressive treatment
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
As AI promises to revolutionize medical note-taking, concerns mount…
As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm
Could a fight over cost-effectiveness upend Medicare drug price…
Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?
Novartis data set up multibillion-dollar battle over breast cancer…
Novartis data set up multibillion-dollar battle over breast cancer drugs

Comments are closed.

Recommended Stories